Scholars Central

Review articlePublished 18 Mar 2025

Personalized Therapies in Hepatocellular Carcinoma: Insights from a Disulfidptosis-Related Signature

Authors: Yi Wan, Dan Xu, Zhiyong Zhou, Yi Ouyang, Zugui Zhang, Li Zhang, Tao Chen, Zheng Gong

1Department of Clinical Laboratory, Jiangxi Medical College, Nanchang University, Nanchang, China; 2Department of Blood Transfusion, The First Hospital of Jiaxing, Jiaxing, China; 3Department of Pathology, The First Affiliated Hospital of Nanchang University, Nanchang, China; 4Department of Pharmaceutics, Qingdao University, Qingdao, China; 5Department of Basic Medicine, Xiangnan University, Chenzhou, China; 6Department of Health Care, Christiana Care Health System, New York, U.S.A; 7Department of Immunology, School of Basic Medicine, Qingdao University, Qingdao, China

Diagnostic Pathology: Open Access

Volume 10 · Issue 1 · Pages 1–6

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Hepatocellular Carcinoma (HCC) is the predominant pathological type of liver cancer with an unfavorable prognosis. Disulfidptosis is the newest cell death form and plays a vital role in tumorigenesis. However, the role of Disulfidptosis-Related Genes (DRGs) in HCC remains unknown. The RNA-seq and clinical data of HCC patients were obtained from The Cancer Genome Atlas (TCGA) and International Cancer Genome Consortium (ICGC) databases. Based on DRGs in TCGA cohort, the predictive model was established via regression analysis of the Least Absolute Shrinkage and Selection Operator (LASSO) and subsequently validated using ICGC cohort. Moreover, we investigated the relationship between predictive model and clinical features, somatic mutations, molecular mechanism, immune microenvironment and drug response. This study created an eight-gene signature. Here, we noticed a higher level of those eight genes in HCC patients in both RNA and protein levels. The patients in the high risk group had a poor prognosis. It was found the predictive model was an independent prognostic factor by Multivariate Cox analyses. Pathways involved in cancer, cell membrane and metabolism was significantly enriched. In addition, Tumor Mutation Burden (TMB) and immune checkpoint genes expression were higher in the high-risk group. Furthermore, the high-risk group was more sensitive to immunotherapy and some targeted therapy. We comprehensively and systematically identified a new disulfidptosis-related signature, which could serve as a valuable tool for predicting prognosis, immune cell infiltration and therapy response of HCC patients. Thus, these discoveries could have potentially clinical value in directing personalized therapies in the future.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalDiagnostic Pathology: Open Access
  • SubjectPathology & Lab Medicine
  • BylineArticles whose byline prints “Yi Wan”
  • BylineArticles whose byline prints “Dan Xu”
  • BylineArticles whose byline prints “Zhiyong Zhou”
  • BylineArticles whose byline prints “Yi Ouyang”
  • BylineArticles whose byline prints “Zugui Zhang”
  • BylineArticles whose byline prints “Li Zhang”
  • BylineArticles whose byline prints “Tao Chen”
  • BylineArticles whose byline prints “Zheng Gong”